Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Modifies Premarin Warnings Slightly

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from estrogen-alone and estrogen-plus-progestin substudies of the Women’s Health Initiative now included in black box for Premarin products.

You may also be interested in...



Wyeth Wins Round One Of 5,000 In Hormone Therapy Suits

Research findings about breast cancer risk from Premarin are mixed, Wyeth maintains.

Wyeth Wins Round One Of 5,000 In Hormone Therapy Suits

Research findings about breast cancer risk from Premarin are mixed, Wyeth maintains.

Estrogen Use Alone Does Not Increase Breast Cancer Risk, JAMA Analysis Finds

Women’s Health Initiative data analysis shows increase in frequency of mammography screenings requiring short-term follow-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel